Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations - 19/04/17
Abstract |
Background |
The effectiveness of bronchial thermoplasty (BT) has been reported in patients with severe asthma, yet its effect on different bronchial structures remains unknown.
Objective |
We sought to examine the effect of BT on bronchial structures and to explore the association with clinical outcome in patients with severe refractory asthma.
Methods |
Bronchial biopsy specimens (n = 300) were collected from 15 patients with severe uncontrolled asthma before and 3 months after BT. Immunostained sections were assessed for airway smooth muscle (ASM) area, subepithelial basement membrane thickness, nerve fibers, and epithelial neuroendocrine cells. Histopathologic findings were correlated with clinical parameters.
Results |
BT significantly improved asthma control and quality of life at both 3 and 12 months and decreased the numbers of severe exacerbations and the dose of oral corticosteroids. At 3 months, this clinical benefit was accompanied by a reduction in ASM area (median values before and after BT, respectively: 19.7% [25th-75th interquartile range (IQR), 15.9% to 22.4%] and 5.3% [25th-75th IQR], 3.5% to 10.1%, P < .001), subepithelial basement membrane thickening (4.4 μm [25th-75th IQR, 4.0-4.7 μm] and 3.9 μm [25th-75th IQR, 3.7-4.6 μm], P = 0.02), submucosal nerves (1.0 ‰ [25th-75th IQR, 0.7-1.3 ‰] immunoreactivity and 0.3 ‰ [25th-75th IQR, 0.1-0.5 ‰] immunoreactivity, P < .001), ASM-associated nerves (452.6 [25th-75th IQR, 196.0-811.2] immunoreactive pixels per mm2 and 62.7 [25th-75th IQR, 0.0-230.3] immunoreactive pixels per mm2, P = .02), and epithelial neuroendocrine cells (4.9/mm2 [25th-75th IQR, 0-16.4/mm2] and 0.0/mm2 [25th-75th IQR, 0-0/mm2], P = .02). Histopathologic parameters were associated based on Asthma Control Test scores, numbers of exacerbations, and visits to the emergency department (all P ≤ .02) 3 and 12 months after BT.
Conclusion |
BT is a treatment option in patients with severe therapy-refractory asthma that downregulates selectively structural abnormalities involved in airway narrowing and bronchial reactivity, particularly ASM, neuroendocrine epithelial cells, and bronchial nerve endings.
El texto completo de este artículo está disponible en PDF.Key words : Refractory asthma, asthma control, airway smooth muscle, airway remodeling, epithelium neuroendocrine cells, mucosal nerves, bronchial epithelium
Abbreviations used : ACT, AQLQ, ASM, BT, FVC, ICU, IQR, OCS, PGP, SBM
Esquema
Supported in part by Boston Scientific, Marlborough, Mass. |
|
Disclosure of potential conflict of interest: M. Pretolani receives grant support from MedImmune. G. Thabut serves as a consultant for GlaxoSmithKline and AstraZeneca and travel support from AstraZeneca. P. Chanez received an honorarium and personal fees from Boston Scientific; serves on the board for Chiesi, Novartis, AstraZeneca, GlaxoSmithKline, TEVA, Boston Scientific, ALK-Abelló, and Sanofi; receives grant support from Roche, AstraZeneca and Jannsen; and receives payments for lectures from Novartis, Boston Scientific, AstraZeneca, Chiesi, and ALK-Abelló. M. Aubier receives grant support from AstraZeneca, GlaxoSmithKline, Roche, and Boston Scientific. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 139 - N° 4
P. 1176-1185 - avril 2017 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?